The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-11. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
In mouse leukemia model driven by fusion oncoprotein, condensate arrest suppressed target gene expression and inhibited cell proliferation. These findings provide mechanistic support for the functional relevance of the condensate microenvironment. Together, these studies establish the condensate microenvironment as a key mechanism in the regulation of biochemical specificity, localization, and activity within cells.
As of 2020, despite the group's rapid expansion, the CJNG does not necessarily control every area it is present in. It is, however, the dominant criminal actor in Jalisco, Nayarit, Colima, the port of Lázaro Cárdenas in Michoacán, the eastern state of Veracruz and in the oil-rich central region of Guanajuato, Puebla, Querétaro and Hidalgo. It is also strong, although facing stern rivalries, in the border cities of Tijuana and Juárez, Tierra Caliente – the area which covers parts of Michoacán, Guerrero, and the State of Mexico, as well as the Riviera Maya. The group has shown it may be focusing on entering the capital, after a brazen attack against Mexico City's public security secretary in June 2020. Internationally, the cartel has contacts in Colombia, Peru, Bolivia, the United States, Central America, Canada, Australia, China and Southeast Asia, which help it control large parts of marijuana, cocaine and synthetic drug trafficking in Mexico. On 31 March 2021, a show of force and a massacre of rivals was reported in the Aguililla municipality, the birthplace of "El Mencho", an avocado growing area and also a center of drug cooking within the Tierra Caliente.
The Pixel Imaging Mass Spectrometry camera (PImMS) is an ultrafast imaging sensor designed for time-of-flight particle imaging. It was invented by professors of chemistry at the University of Oxford, Mark Brouard and Claire Vallance., Renato Turchetta from IMASENIC (formerly at the STFC Rutherford Appleton Laboratory), and Andrei Nomerotski from Brookhaven National Labs (formerly at the Department of Physics, University of Oxford). The camera and accompanying software have been further developed by Iain Sedgwick (STFC Rutherford Appleton Laboratory), Jaya John John (Department of Physics, University of Oxford), and Jason Lee (Department of Chemistry, University of Oxford). The camera has been used for studies in chemical reaction dynamics, imaging mass spectrometry, and neutron time-of-flight imaging.
In 2023, Tiu Laurel was appointed by President Bongbong Marcos as secretary of agriculture. The post was previously held by Marcos himself. Before his appointment, Tiu Laurel divested his interests from his companies, following concerns of conflict of interest with the position. On May 22, 2025, Tiu Laurel, along with other cabinet secretaries, were forced by President Marcos to tender courtesy resignations from their respective posts after the President called for a cabinet overhaul in the aftermath of the May 12, 2025, midterm elections. Tiu Laurel was ultimately retained.
Sources: en.wikipedia.org
The web was completed the following day. The crew members were prompted to expand the initial protocol. They fed and watered the spiders, giving them a house fly. The first web was removed on August 13 to allow the spider to construct a second web. At first, the spider failed to construct a new web. When given more water, it built a second web. This time, it was more elaborate than the first. Both spiders died during the mission, possibly from dehydration. When scientists were given the opportunity to study the webs, they discovered that the space webs were finer than normal Earth webs, and although the patterns of the web were not totally dissimilar, variations were spotted, and there was a definite difference in the characteristics of the web. Additionally, while the webs were finer overall, the space web had variations in thickness in places: some places were slightly thinner, and others slightly thicker. This was unusual, because Earth webs have been observed to have uniform thickness. Later experiments indicated that having access to a light source could orient the spiders and enable them to build their normal asymmetric webs when gravity was not a factor.
== Joining chain == Chains are usually bought ready-joined to length, to suit a particular bar. All chainsaws have adjustable bar mounts to allow their chain tightness to be adjusted, allowing for any wear in the chain linkages. There is no requirement to remove links to shorten worn chains, chains will wear out on their cutting teeth before wear in their pivots becomes a problem. The adjustment also permits enough slack to allow a chain to be installed, so there is no need for a "split link" when fitting, as for bicycles. Large scale operators and retail shops may buy bulk chain on reels. This must then be cut and joined to length which is done by inserting rivet pins. These non-reusable pins are usually supplied already installed into a half-link and must be peened over against a half-link on the other side. As this peening is done with a bench-mounted rotary tool, rather than hammering, it is referred to as "rivet spinning". The tool is usually hand-cranked, or may be electrically powered for mass production.
In early stages of keratoconus, glasses or soft contact lenses can suffice to correct for the mild astigmatism. As the condition progresses, these may no longer provide the person with a satisfactory degree of visual acuity, and most practitioners will move to manage the condition with rigid contact lenses, known as rigid, gas-permeable, (RGP) lenses. RGP lenses provide a good level of visual correction, but do not arrest progression of the condition. In people with keratoconus, rigid contact lenses improve vision by means of tear fluid filling the gap between the irregular corneal surface and the smooth regular inner surface of the lens, thereby creating the effect of a smoother cornea. Many specialized types of contact lenses have been developed for keratoconus, and affected people may seek out both doctors specialized in conditions of the cornea, and contact lens fitters who have experience managing people with keratoconus. The irregular cone presents a challenge and the fitter will endeavor to produce a lens with the optimal contact, stability and steepness. Some trial-and-error fitting may prove necessary.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.